Journal
JOURNAL OF MATERIALS CHEMISTRY B
Volume 10, Issue 2, Pages 224-235Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/d1tb02256c
Keywords
-
Categories
Funding
- NCI [U01CA198892, R01CA253627]
- Case Comprehensive Cancer Center Support Grant [P30CA043703]
- Shiverick Family Fund
- Clinical Translational Science Collaborative of Cleveland [UL1TR002548]
- Alex's Lemonade Stand Foundation
- NIH Interdisciplinary Biomedical Imaging Training Program [T32EB007509]
- National Science Foundation
Ask authors/readers for more resources
A novel immunostimulatory nanoparticle was developed to reprogram tumor antigen-presenting cells and activate cytotoxic T cells in the tumor microenvironment, showing potential for inhibiting tumor growth. Both untargeted nanoparticles and integrin-targeting nanoparticles exhibited significant immune responses and long-lasting antitumor effects.
To alter the immunosuppressive tumor microenvironment (TME), we developed an immunostimulatory nanoparticle (NP) to reprogram a tumor's dysfunctional and inhibitory antigen-presenting cells (APCs) into properly activated APCs that stimulate tumor-reactive cytotoxic T cells. Importantly, systemic delivery allowed NPs to efficiently utilize the entire microvasculature and gain access into the majority of the perivascular TME, which coincided with the APC-rich tumor areas leading to uptake of the NPs predominantly by APCs. In this work, a 60 nm NP was loaded with a STING agonist, which triggered robust production of interferon beta, resulting in activation of APCs. In addition to untargeted NPs, we employed 'mainstream' ligands targeting fibronectin, alpha(v)beta(3) integrin and P-selectin that are commonly used to direct nanoparticles to tumors. Using the 4T1 mouse model, we assessed the microdistribution of the four NP variants in the tumor immune microenvironment in three different breast cancer landscapes, including primary tumor, early metastasis, and late metastasis. The different NP variants resulted in variable uptake by immune cell subsets depending on the organ and tumor stage. Among the NP variants, therapeutic studies indicated that the untargeted NPs and the integrin-targeting NPs exhibited a remarkable short- and long-term immune response and long-lasting antitumor effect.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available